Press Release

Ashvattha Therapeutics Reports the Ability to Tune Nanomedicines to Image Neuroinflammation in Multiple Sclerosis Patients and Tumor Associated Macrophages in Cancer at SNMMI Annual Meeting

by

Novel nanomedicine radiotracer crosses blood brain barrier in patients with neuroinflammation  Tumor macrophage radiotracer achieves 41.6% peak tumor uptake in preclinical studies  REDWOOD CITY, Calif., June 23, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions … Read more

Ashvattha Therapeutics to Present Data on Novel Nanomedicine Radiotracers at SNMMI Annual Meeting

by

Company to showcase breakthrough imaging agents advancing precision medicine in neurology and oncology   REDWOOD CITY, Calif., June 17, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced it will present data … Read more

Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Data at Clinical Trials at the Summit and MaculArt

by

Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments  Company is exploring new technology to normalize VEGF expression, potentially enhancing both safety and efficacy of treatments for retinal and other diseases   REDWOOD CITY, Calif., June 10, … Read more

Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO

by

Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in fellow eyes Maintenance of vision and anatomical improvements in study eye and fellow eye of patients previously treated First-in-class dendrimer nanomedicine that treats both eyes simultaneously with … Read more

Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting

by

Presentations to highlight updated Phase 2 subcutaneous migaldendranib (MGB) data for wet AMD and DME REDWOOD CITY, Calif., April 15, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced it will present … Read more

Ashvattha Therapeutics Accelerates Clinical Development Strategy with Leadership Appointment of Six Leading Retinal Specialists to Clinical Advisory Board

by

New Clinical Advisory Board brings together distinguished retinal specialists to provide strategic guidance on development of Ashvattha’s innovative nanomedicine programs REDWOOD CITY, Calif., Mar. 18, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, … Read more

Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference

by

Multiple subcutaneous doses safe and well-tolerated   >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes   >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral disease patients  Maintenance of BCVA and reduction of CST in these previously treated patients  Migaldendranib therapy obviates or reduces the need for more invasive in-the-eye injections  REDWOOD … Read more

Ashvattha to Present at Upcoming Angiogenesis, Exudation, and Degeneration 2025 and BIO CEO Conferences

by

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced upcoming presentations at Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025 and the … Read more

Ashvattha Therapeutics Announces $50 Million Financing Extension and Interim Phase 2 Ophthalmology Trial Results

by

Ashvattha receives additional financing up to $50 million with new lead investor Tribe Capital and existing investors led by Natural Capital Ashvattha’s at-home monthly subcutaneously-administered HDT (hydroxyl dendrimer therapeutic) for neovascular (wet) age-related macular degeneration (wet AMD) and diabetic macula edema (DME) demonstrated substantial reduction in treatment burden Interim Phase 2 trial results to be … Read more

Presentation at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting Highlights Ashvattha Product Candidates for Neuroinflammation Imaging and Treatment

by

Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE model Ashvattha’s 18F-OP-801 PET imaging agent shows reduction in neuroinflammation following treatment with CSF1R dendranib Presentation by Stanford University collaborator nominated for Brain Imaging Council Young Investigator Award at … Read more